Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Taffet Gold

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Health Affairs (Project Hope)|July 9, 2008
Caring and compromiseHeather Taffet Gold
Journal of the National Cancer Institute|June 3, 2004
Re: Trends in the treatment of ductal carcinoma in situ of the breastHeather Taffet Gold, Andrew W Dick
Medical Care|April 13, 2004
Variations in treatment for ductal carcinoma in situ in elderly womenHeather Taffet Gold, Andrew W Dick
Breast Cancer Research and Treatment|September 18, 2012
Cost effectiveness of new breast cancer radiotherapy technologies in diverse populationsHeather Taffet Gold, Mary Katherine Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Antifungal prophylaxis for allogeneic hematopoietic cell transplantationDeborah Braccia, Patricia Stone, Heather Taffet Gold
Cancer|October 22, 2008
Correlates and effect of suboptimal radiotherapy in women with ductal carcinoma in situ or early invasive breast cancerHeather Taffet Gold, Huong T Do, Andrew W Dick
Breast Cancer Research and Treatment|January 21, 2014
Treatment and outcomes in diabetic breast cancer patientsHeather Taffet Gold, Nour Makarem, Joseph M Nicholson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 11, 2014
Decision to adopt medical technology: case study of breast cancer radiotherapy techniquesHeather Taffet Gold, Kimberly Pitrelli, Mary Katherine Hayes, et al.
Cancer|June 12, 2009
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancerHeather Taffet Gold, Michael J Hall, Victoria Blinder, et al.
Pharmacoeconomics|April 6, 2004
How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?Bruce R Schackman, Heather Taffet Gold, Patricia W Stone, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Health Affairs (Project Hope)|July 9, 2008
Caring and compromiseHeather Taffet Gold
Journal of the National Cancer Institute|June 3, 2004
Re: Trends in the treatment of ductal carcinoma in situ of the breastHeather Taffet Gold, Andrew W Dick
Medical Care|April 13, 2004
Variations in treatment for ductal carcinoma in situ in elderly womenHeather Taffet Gold, Andrew W Dick
Breast Cancer Research and Treatment|September 18, 2012
Cost effectiveness of new breast cancer radiotherapy technologies in diverse populationsHeather Taffet Gold, Mary Katherine Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Antifungal prophylaxis for allogeneic hematopoietic cell transplantationDeborah Braccia, Patricia Stone, Heather Taffet Gold
Cancer|October 22, 2008
Correlates and effect of suboptimal radiotherapy in women with ductal carcinoma in situ or early invasive breast cancerHeather Taffet Gold, Huong T Do, Andrew W Dick
Breast Cancer Research and Treatment|January 21, 2014
Treatment and outcomes in diabetic breast cancer patientsHeather Taffet Gold, Nour Makarem, Joseph M Nicholson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 11, 2014
Decision to adopt medical technology: case study of breast cancer radiotherapy techniquesHeather Taffet Gold, Kimberly Pitrelli, Mary Katherine Hayes, et al.
Cancer|June 12, 2009
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancerHeather Taffet Gold, Michael J Hall, Victoria Blinder, et al.
Pharmacoeconomics|April 6, 2004
How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?Bruce R Schackman, Heather Taffet Gold, Patricia W Stone, et al.
Pageof 2